A Phase 1/2 interventional study of CDP6038 and CDP6038 in Arthritis and Rheumatoid Arthritis, sponsored by UCB Pharma. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-15.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is the only one that started in 2009, is the only one in phase 1/2, and was the 1st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 1 started in 2009.
This study's enrollment of 40 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
42 studies in Arthritis, Rheumatoid by UCB S.A.: 1 open now, 2 under way, none of them phase 3. Of 39 finished, 26 (67%) have results posted.
Among the 42 studies in Arthritis, Rheumatoid by UCB S.A., this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2009, is the only one in phase 1/2, and was the 14th registered.
UCB S.A.’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 42 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be evaluated.
The secondary objectives of the study include determination of the absolute bioavailability of CDP6038 given via sc administration compared with iv infusion; assessment of the immunogenicity potential of single dose CDP6038 and assessment, on an exploratory basis, of other relevant systemic biomarkers and changes in clinical response.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
This study's enrollment of 40 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
Biological: CDP6038 · Other: Placebo IV · Drug: Methotrexate
Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
Biological: CDP6038 · Other: Placebo SC · Drug: Methotrexate
Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
Drug: CDP 6038 SC · Drug: Methotrexate
Single dose: 1 mg/kg CDP6038 IV
Single dose: 0.1mg/kg CDP6038 IV
Single dose: 1.0mg/kg CDP6038 SC
Single dose: Placebo IV
Single dose: Placebo SC
Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
Individual stable doses of methotrexate.
PK/PD relationship between systemic CDP6038 exposure and CRP suppression.
Time frame: For 12 weeks following single dose
Evaluate the safety and tolerability of single doses of CDP6038 For 12 weeks following single dose
Time frame: For 12 weeks following single dose
Absolute bioavailability of CDP6038 given by sc injection in comparison with iv infusion
Time frame: For 12 weeks following single dose
Assess the immunogenicity of single dose CDP6038
Time frame: Multiple sampling from 0 to 12 weeks following single dose
Assess, on an exploratory basis, changes in clinical response and other systemic biomarkers associated with RA
Time frame: For 12 weeks following single dose
Ran from Oct 2009 to primary completion in Sep 2010, 11 months.
Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab